India is transitioning from a provider of low-cost generic drugs to a global innovation powerhouse for pharmaceutical markets, according to Cipla leadership.
This shift represents a strategic pivot for one of the world's largest medicine producers. By moving toward high-value research and development, India aims to lead the creation of new therapeutic molecules rather than simply replicating existing ones.
Achin Gupta, Managing Director and Global CEO of Cipla, discussed this evolution during an interview with CNBC TV18. He said that the industry is leveraging advances in biologics, artificial intelligence, and growing scale to fuel a new wave of breakthroughs.
"India is evolving from being the 'pharmacy of the world' to an innovation powerhouse for global markets," Gupta said.
The transition is supported by the country's existing industrial footprint. India's pharmaceutical sector currently ranks as the 11th-largest globally by value [1]. This scale provides a foundation for the integration of AI and biologics into the manufacturing pipeline.
Trade dynamics are also shifting to support this growth. U.S. tariffs on Indian pharmaceutical exports are being reduced from 50% to 18% [2]. This reduction in trade barriers may lower the cost of entry for innovative Indian products into the American market.
Gupta said that the combination of research capabilities and industrial scale is allowing the sector to move beyond its traditional role. The integration of AI is expected to accelerate the discovery of new drugs and optimize the development of complex biologics.
“India is evolving from being the "pharmacy of the world" to an innovation powerhouse for global markets.”
The transition from a generics-led model to an innovation-led model indicates a maturation of the Indian biotech ecosystem. By combining AI-driven R&D with a significant reduction in US trade tariffs, India is positioning itself to compete directly with Western pharmaceutical giants in the development of proprietary, high-margin medicines.
